TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) Short Interest Up 146.2% in July

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) saw a significant growth in short interest in July. As of July 15th, there was short interest totalling 3,200 shares, a growth of 146.2% from the June 30th total of 1,300 shares. Based on an average daily trading volume, of 13,500 shares, the days-to-cover ratio is currently 0.2 days.

TriSalus Life Sciences Stock Down 3.0 %

TLSIW stock opened at $1.60 on Friday. TriSalus Life Sciences has a one year low of $0.09 and a one year high of $2.23. The firm has a 50-day moving average of $1.59 and a two-hundred day moving average of $1.21.

Institutional Trading of TriSalus Life Sciences

Hedge funds have recently bought and sold shares of the company. Clear Street LLC purchased a new stake in TriSalus Life Sciences during the fourth quarter valued at about $60,000. Wolverine Asset Management LLC purchased a new stake in TriSalus Life Sciences during the fourth quarter valued at about $123,000. Finally, Highbridge Capital Management LLC lifted its stake in TriSalus Life Sciences by 9.4% during the fourth quarter. Highbridge Capital Management LLC now owns 397,825 shares of the company’s stock valued at $473,000 after buying an additional 34,067 shares in the last quarter.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.